Amgen Inc. (NASDAQ:AMGN) – Investment analysts at Jefferies Group increased their Q3 2017 earnings estimates for shares of Amgen in a research note issued to investors on Tuesday. Jefferies Group analyst M. Yee now anticipates that the medical research company will post earnings per share of $3.16 for the quarter, up from their previous forecast of $3.13. Jefferies Group currently has a “Buy” rating and a $195.00 target price on the stock. Jefferies Group also issued estimates for Amgen’s Q4 2017 earnings at $2.99 EPS and FY2018 earnings at $13.01 EPS.

AMGN has been the topic of a number of other reports. Deutsche Bank AG started coverage on shares of Amgen in a research note on Friday, June 23rd. They set a “hold” rating and a $172.00 target price on the stock. Credit Suisse Group restated a “hold” rating and set a $178.00 target price on shares of Amgen in a research note on Tuesday, April 4th. ValuEngine lowered shares of Amgen from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Oppenheimer Holdings, Inc. set a $189.00 target price on shares of Amgen and gave the stock a “buy” rating in a research note on Monday, June 5th. Finally, Mizuho restated a “buy” rating and set a $195.00 target price on shares of Amgen in a research note on Monday, April 3rd. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, eleven have assigned a buy rating and three have assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $186.81.

ILLEGAL ACTIVITY WARNING: “Q3 2017 EPS Estimates for Amgen Inc. (NASDAQ:AMGN) Boosted by Jefferies Group” was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/07/28/q3-2017-eps-estimates-for-amgen-inc-nasdaqamgn-boosted-by-jefferies-group.html.

Shares of Amgen (NASDAQ:AMGN) opened at 172.15 on Friday. The stock has a 50 day moving average of $172.14 and a 200-day moving average of $166.19. The company has a market capitalization of $126.60 billion, a PE ratio of 16.35 and a beta of 1.36. Amgen has a 12-month low of $133.64 and a 12-month high of $184.21.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, beating analysts’ consensus estimates of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The business had revenue of $5.81 billion for the quarter, compared to analysts’ expectations of $5.67 billion. During the same period last year, the business earned $2.84 EPS. The company’s revenue was up 2.1% compared to the same quarter last year.

In related news, SVP Cynthia M. Patton sold 2,922 shares of the stock in a transaction on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the completion of the sale, the senior vice president now directly owns 24,214 shares of the company’s stock, valued at $3,738,641.60. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.20% of the stock is currently owned by corporate insiders.

Large investors have recently modified their holdings of the company. Ancora Advisors LLC increased its stake in shares of Amgen by 48.3% in the fourth quarter. Ancora Advisors LLC now owns 7,239 shares of the medical research company’s stock valued at $1,058,000 after buying an additional 2,359 shares in the last quarter. Focused Wealth Management Inc increased its stake in shares of Amgen by 248.0% in the fourth quarter. Focused Wealth Management Inc now owns 870 shares of the medical research company’s stock valued at $127,000 after buying an additional 620 shares in the last quarter. Banco Santander S.A. bought a new stake in shares of Amgen during the fourth quarter valued at $798,000. Guggenheim Capital LLC increased its stake in shares of Amgen by 7.3% in the fourth quarter. Guggenheim Capital LLC now owns 725,359 shares of the medical research company’s stock valued at $106,055,000 after buying an additional 49,543 shares in the last quarter. Finally, AQR Capital Management LLC increased its stake in shares of Amgen by 7.1% in the fourth quarter. AQR Capital Management LLC now owns 1,050,591 shares of the medical research company’s stock valued at $153,607,000 after buying an additional 69,264 shares in the last quarter. 78.87% of the stock is owned by hedge funds and other institutional investors.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Earnings History and Estimates for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.